Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystic Fibrosis | 27 | 2024 | 151 | 13.430 |
Why?
|
| Quinolones | 16 | 2024 | 42 | 8.930 |
Why?
|
| Aminophenols | 17 | 2024 | 18 | 8.030 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 18 | 2024 | 36 | 6.670 |
Why?
|
| Benzodioxoles | 9 | 2024 | 41 | 3.900 |
Why?
|
| Indoles | 6 | 2024 | 273 | 3.030 |
Why?
|
| Pyrazoles | 6 | 2024 | 110 | 2.760 |
Why?
|
| Pyridines | 6 | 2024 | 132 | 2.060 |
Why?
|
| Epithelial Cells | 6 | 2024 | 209 | 1.830 |
Why?
|
| Pyrrolidines | 5 | 2024 | 67 | 1.760 |
Why?
|
| Nasal Mucosa | 3 | 2021 | 19 | 1.590 |
Why?
|
| Drug Combinations | 4 | 2024 | 126 | 1.340 |
Why?
|
| Organoids | 3 | 2021 | 36 | 1.120 |
Why?
|
| Molecular Targeted Therapy | 2 | 2018 | 121 | 1.110 |
Why?
|
| Tandem Mass Spectrometry | 3 | 2024 | 227 | 1.090 |
Why?
|
| Mutation | 8 | 2023 | 1291 | 1.080 |
Why?
|
| Feasibility Studies | 2 | 2024 | 382 | 0.990 |
Why?
|
| Neonatal Screening | 1 | 2024 | 47 | 0.910 |
Why?
|
| Cross-Over Studies | 1 | 2024 | 223 | 0.910 |
Why?
|
| Tacrolimus | 1 | 2021 | 57 | 0.720 |
Why?
|
| Humans | 32 | 2024 | 49877 | 0.710 |
Why?
|
| Liver Transplantation | 1 | 2021 | 151 | 0.660 |
Why?
|
| Genetic Therapy | 1 | 2020 | 117 | 0.650 |
Why?
|
| Rhodospirillaceae | 1 | 2018 | 1 | 0.620 |
Why?
|
| Staphylococcal Infections | 2 | 2018 | 269 | 0.600 |
Why?
|
| Spheroids, Cellular | 1 | 2017 | 24 | 0.590 |
Why?
|
| Rifampin | 1 | 2018 | 62 | 0.590 |
Why?
|
| Adult | 10 | 2024 | 13344 | 0.510 |
Why?
|
| Anti-Bacterial Agents | 2 | 2018 | 742 | 0.500 |
Why?
|
| Young Adult | 6 | 2024 | 4027 | 0.490 |
Why?
|
| Chromatography, Liquid | 3 | 2024 | 225 | 0.480 |
Why?
|
| Antineoplastic Agents | 1 | 2023 | 1175 | 0.470 |
Why?
|
| Adolescent | 8 | 2024 | 6402 | 0.430 |
Why?
|
| Sweat | 2 | 2024 | 7 | 0.410 |
Why?
|
| Child | 9 | 2024 | 6826 | 0.390 |
Why?
|
| Ion Transport | 2 | 2021 | 16 | 0.390 |
Why?
|
| Female | 11 | 2024 | 26555 | 0.380 |
Why?
|
| Genotype | 2 | 2023 | 539 | 0.350 |
Why?
|
| Pilot Projects | 2 | 2024 | 702 | 0.350 |
Why?
|
| Male | 10 | 2024 | 25427 | 0.340 |
Why?
|
| Pseudomonas Infections | 2 | 2020 | 47 | 0.330 |
Why?
|
| Quality of Life | 4 | 2023 | 836 | 0.290 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2018 | 77 | 0.280 |
Why?
|
| Pyrroles | 2 | 2024 | 68 | 0.280 |
Why?
|
| Cell Line | 3 | 2024 | 1010 | 0.260 |
Why?
|
| Oxygen | 1 | 2008 | 321 | 0.250 |
Why?
|
| Respiratory Mucosa | 1 | 2024 | 10 | 0.240 |
Why?
|
| Chlorides | 2 | 2024 | 49 | 0.230 |
Why?
|
| Dietary Fats | 1 | 2024 | 124 | 0.230 |
Why?
|
| Quinolines | 1 | 2024 | 41 | 0.230 |
Why?
|
| United States | 3 | 2024 | 4873 | 0.220 |
Why?
|
| Gene Expression Regulation | 1 | 2008 | 964 | 0.220 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2023 | 40 | 0.220 |
Why?
|
| Pseudomonas aeruginosa | 2 | 2020 | 71 | 0.210 |
Why?
|
| Lung Transplantation | 1 | 2023 | 37 | 0.210 |
Why?
|
| Pharmacogenetics | 1 | 2023 | 50 | 0.210 |
Why?
|
| Diet, High-Fat | 1 | 2024 | 214 | 0.210 |
Why?
|
| Body Composition | 1 | 2024 | 320 | 0.200 |
Why?
|
| Drug Prescriptions | 1 | 2023 | 95 | 0.200 |
Why?
|
| Insurance, Health | 1 | 2023 | 131 | 0.200 |
Why?
|
| Forced Expiratory Volume | 2 | 2020 | 44 | 0.190 |
Why?
|
| Nose | 1 | 2021 | 31 | 0.190 |
Why?
|
| Mutant Proteins | 1 | 2020 | 37 | 0.180 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2024 | 1354 | 0.180 |
Why?
|
| Respiratory Function Tests | 1 | 2020 | 88 | 0.180 |
Why?
|
| Treatment Outcome | 3 | 2024 | 5174 | 0.170 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 378 | 0.170 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 226 | 0.170 |
Why?
|
| Asthma | 1 | 2023 | 282 | 0.160 |
Why?
|
| Stenotrophomonas maltophilia | 1 | 2018 | 6 | 0.150 |
Why?
|
| Amikacin | 1 | 2018 | 19 | 0.150 |
Why?
|
| Phenotype | 2 | 2020 | 728 | 0.150 |
Why?
|
| Clindamycin | 1 | 2018 | 13 | 0.150 |
Why?
|
| Ciprofloxacin | 1 | 2018 | 21 | 0.150 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 693 | 0.150 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2018 | 42 | 0.150 |
Why?
|
| Body Weight | 1 | 2020 | 512 | 0.150 |
Why?
|
| Case-Control Studies | 1 | 2021 | 1129 | 0.150 |
Why?
|
| Aminopyridines | 1 | 2017 | 15 | 0.150 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2018 | 77 | 0.150 |
Why?
|
| Virulence | 1 | 2018 | 171 | 0.140 |
Why?
|
| Particle Size | 1 | 2017 | 79 | 0.140 |
Why?
|
| Drug Interactions | 1 | 2018 | 207 | 0.140 |
Why?
|
| Biological Transport | 1 | 2017 | 170 | 0.140 |
Why?
|
| Tracheostomy | 1 | 2018 | 71 | 0.140 |
Why?
|
| Nutritional Status | 1 | 2018 | 136 | 0.140 |
Why?
|
| Infant, Newborn | 1 | 2024 | 2727 | 0.140 |
Why?
|
| Telemedicine | 1 | 2023 | 465 | 0.140 |
Why?
|
| Medication Adherence | 1 | 2018 | 130 | 0.140 |
Why?
|
| Cells, Cultured | 1 | 2020 | 1587 | 0.130 |
Why?
|
| Risk Factors | 1 | 2024 | 3608 | 0.130 |
Why?
|
| Middle Aged | 3 | 2024 | 12289 | 0.120 |
Why?
|
| Prospective Studies | 1 | 2020 | 2342 | 0.120 |
Why?
|
| Lung | 3 | 2023 | 501 | 0.110 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 2176 | 0.100 |
Why?
|
| Retrospective Studies | 2 | 2018 | 6118 | 0.080 |
Why?
|
| Culture Media, Conditioned | 1 | 2008 | 48 | 0.080 |
Why?
|
| Cell Hypoxia | 1 | 2008 | 82 | 0.070 |
Why?
|
| Down-Regulation | 1 | 2008 | 342 | 0.070 |
Why?
|
| Codon, Nonsense | 1 | 2023 | 26 | 0.060 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2024 | 47 | 0.060 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2003 | 23 | 0.060 |
Why?
|
| Sarcoma, Ewing | 1 | 2003 | 27 | 0.050 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2003 | 59 | 0.050 |
Why?
|
| Smoke | 1 | 2023 | 18 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 1 | 2008 | 1777 | 0.050 |
Why?
|
| Transaminases | 1 | 2022 | 11 | 0.050 |
Why?
|
| Patient-Centered Care | 1 | 2023 | 129 | 0.050 |
Why?
|
| Fibroblasts | 1 | 2003 | 352 | 0.050 |
Why?
|
| Mice | 2 | 2008 | 5657 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2003 | 565 | 0.040 |
Why?
|
| North Carolina | 1 | 2018 | 53 | 0.040 |
Why?
|
| Respiratory System | 1 | 2018 | 27 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2020 | 205 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2022 | 1406 | 0.040 |
Why?
|
| Sex Factors | 1 | 2020 | 691 | 0.040 |
Why?
|
| Animals | 3 | 2008 | 13098 | 0.040 |
Why?
|
| Cross Infection | 1 | 2018 | 94 | 0.040 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2018 | 171 | 0.040 |
Why?
|
| Disease Progression | 1 | 2020 | 820 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2020 | 648 | 0.030 |
Why?
|
| Age Factors | 1 | 2020 | 1090 | 0.030 |
Why?
|
| Prosthesis-Related Infections | 1 | 2018 | 106 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2018 | 223 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2018 | 659 | 0.030 |
Why?
|
| Length of Stay | 1 | 2018 | 624 | 0.030 |
Why?
|
| Staphylococcus aureus | 1 | 2018 | 327 | 0.030 |
Why?
|
| Infant | 1 | 2018 | 3564 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2018 | 3863 | 0.020 |
Why?
|
| Precipitin Tests | 1 | 2004 | 33 | 0.010 |
Why?
|
| Biotinylation | 1 | 2004 | 26 | 0.010 |
Why?
|
| COS Cells | 1 | 2004 | 73 | 0.010 |
Why?
|
| Multienzyme Complexes | 1 | 2004 | 35 | 0.010 |
Why?
|
| Cysteine Endopeptidases | 1 | 2004 | 67 | 0.010 |
Why?
|
| Proto-Oncogene Protein c-fli-1 | 1 | 2003 | 8 | 0.010 |
Why?
|
| Glycosylation | 1 | 2004 | 102 | 0.010 |
Why?
|
| Lymphokines | 1 | 2003 | 20 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2003 | 110 | 0.010 |
Why?
|
| RNA-Binding Protein EWS | 1 | 2003 | 14 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2004 | 165 | 0.010 |
Why?
|
| HeLa Cells | 1 | 2004 | 257 | 0.010 |
Why?
|
| Mice, SCID | 1 | 2003 | 173 | 0.010 |
Why?
|
| Transfection | 1 | 2004 | 354 | 0.010 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2004 | 116 | 0.010 |
Why?
|
| Endoplasmic Reticulum | 1 | 2004 | 118 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 2003 | 111 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2004 | 249 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 579 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2003 | 181 | 0.010 |
Why?
|
| Golgi Apparatus | 1 | 2004 | 114 | 0.010 |
Why?
|
| Kinetics | 1 | 2004 | 632 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2003 | 587 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2003 | 446 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2003 | 824 | 0.010 |
Why?
|
| Time Factors | 1 | 2004 | 2890 | 0.010 |
Why?
|